Suppr超能文献

在小鼠、兔和猴体内比较 ST-246® 静脉输注和口服给药的安全性和药代动力学。

Comparison of the safety and pharmacokinetics of ST-246® after i.v. infusion or oral administration in mice, rabbits and monkeys.

机构信息

SIGA Technologies, Corvallis, Oregon, United States of America.

出版信息

PLoS One. 2011;6(8):e23237. doi: 10.1371/journal.pone.0023237. Epub 2011 Aug 15.

Abstract

BACKGROUND

ST-246® is an antiviral, orally bioavailable small molecule in clinical development for treatment of orthopoxvirus infections. An intravenous (i.v.) formulation may be required for some hospitalized patients who are unable to take oral medication. An i.v. formulation has been evaluated in three species previously used in evaluation of both efficacy and toxicology of the oral formulation.

METHODOLOGY/PRINCIPAL FINDINGS: The pharmacokinetics of ST-246 after i.v. infusions in mice, rabbits and nonhuman primates (NHP) were compared to those obtained after oral administration. Ten minute i.v. infusions of ST-246 at doses of 3, 10, 30, and 75 mg/kg in mice produced peak plasma concentrations ranging from 16.9 to 238 µg/mL. Elimination appeared predominately first-order and exposure dose-proportional up to 30 mg/kg. Short i.v. infusions (5 to 15 minutes) in rabbits resulted in rapid distribution followed by slower elimination. Intravenous infusions in NHP were conducted at doses of 1 to 30 mg/kg. The length of single infusions in NHP ranged from 4 to 6 hours. The pharmacokinetics and tolerability for the two highest doses were evaluated when administered as two equivalent 4 hour infusions initiated 12 hours apart. Terminal elimination half-lives in all species for oral and i.v. infusions were similar. Dose-limiting central nervous system effects were identified in all three species and appeared related to high C(max) plasma concentrations. These effects were eliminated using slower i.v. infusions.

CONCLUSIONS/SIGNIFICANCE: Pharmacokinetic profiles after i.v. infusion compared to those observed after oral administration demonstrated the necessity of longer i.v. infusions to (1) mimic the plasma exposure observed after oral administration and (2) avoid C(max) associated toxicity. Shorter infusions at higher doses in NHP resulted in decreased clearance, suggesting saturated distribution or elimination. Elimination half-lives in all species were similar between oral and i.v. administration. The administration of ST-246 was well tolerated as a slow i.v. infusion.

摘要

背景

ST-246® 是一种抗病毒的、可口服的小分子药物,目前正在开发中,用于治疗正痘病毒感染。对于一些不能口服药物的住院患者,可能需要静脉(i.v.)制剂。先前已经在三种动物(用于评估口服制剂的疗效和毒性)中评估了静脉制剂。

方法/主要发现:在小鼠、兔和非人灵长类动物(NHP)中比较了静脉输注 ST-246 后的药代动力学与口服给药后的药代动力学。在小鼠中,以 3、10、30 和 75mg/kg 的剂量进行 10 分钟静脉输注,得到的峰值血浆浓度范围为 16.9 至 238μg/ml。消除似乎主要是一级,在 30mg/kg 以下呈剂量比例。在兔中进行短暂的静脉输注(5 至 15 分钟),导致快速分布,随后缓慢消除。在 NHP 中进行静脉输注,剂量为 1 至 30mg/kg。NHP 中单次输注的长度为 4 至 6 小时。当以两次相等的 4 小时输注(间隔 12 小时)开始时,评估了两种最高剂量的药代动力学和耐受性。所有物种口服和静脉输注的终末消除半衰期相似。所有三种动物均发现剂量限制的中枢神经系统作用,这似乎与高 C(max)血浆浓度有关。使用较慢的静脉输注可以消除这些作用。

结论/意义:与口服给药后观察到的药代动力学特征相比,静脉输注后的药代动力学特征表明,需要更长的静脉输注时间来(1)模拟口服给药后的血浆暴露,(2)避免与 C(max)相关的毒性。在 NHP 中,更高剂量的较短输注导致清除率降低,表明分布或消除饱和。所有物种的消除半衰期在口服和静脉给药之间相似。作为缓慢的静脉输注,ST-246 的给药具有良好的耐受性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/506c/3156126/ee33c6f57056/pone.0023237.g001.jpg

相似文献

2
Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects.
Antimicrob Agents Chemother. 2010 Jun;54(6):2560-6. doi: 10.1128/AAC.01689-09. Epub 2010 Apr 12.
3
Safety and pharmacokinetics of the anti-orthopoxvirus compound ST-246 following a single daily oral dose for 14 days in human volunteers.
Antimicrob Agents Chemother. 2012 Sep;56(9):4900-5. doi: 10.1128/AAC.00904-12. Epub 2012 Jul 9.
4
Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor.
Antimicrob Agents Chemother. 2008 May;52(5):1721-7. doi: 10.1128/AAC.01303-07. Epub 2008 Mar 3.
6
Oral Tecovirimat for the Treatment of Smallpox.
N Engl J Med. 2018 Jul 5;379(1):44-53. doi: 10.1056/NEJMoa1705688.
9
ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification.
Antimicrob Agents Chemother. 2009 May;53(5):1817-22. doi: 10.1128/AAC.01596-08. Epub 2009 Feb 17.

引用本文的文献

1
Potential use of cidofovir, brincidofovir, and tecovirimat drugs in fighting monkeypox infection: recent trends and advancements.
Naunyn Schmiedebergs Arch Pharmacol. 2024 Apr;397(4):2055-2065. doi: 10.1007/s00210-023-02769-y. Epub 2023 Oct 14.
3
Monkeypox Virus Infections in Humans.
Clin Microbiol Rev. 2022 Dec 21;35(4):e0009222. doi: 10.1128/cmr.00092-22. Epub 2022 Nov 14.
4
Antivirals With Activity Against Mpox: A Clinically Oriented Review.
Clin Infect Dis. 2023 Jan 6;76(1):155-164. doi: 10.1093/cid/ciac622.
9
Pharmacokinetic and pharmacodynamic modeling to determine the dose of ST-246 to protect against smallpox in humans.
Antimicrob Agents Chemother. 2013 Mar;57(3):1136-43. doi: 10.1128/AAC.00959-12. Epub 2012 Dec 17.
10
Safety and pharmacokinetics of the anti-orthopoxvirus compound ST-246 following a single daily oral dose for 14 days in human volunteers.
Antimicrob Agents Chemother. 2012 Sep;56(9):4900-5. doi: 10.1128/AAC.00904-12. Epub 2012 Jul 9.

本文引用的文献

1
Development of ST-246® for Treatment of Poxvirus Infections.
Viruses. 2010 Nov;2(11):2409-2435. doi: 10.3390/v2112409. Epub 2010 Nov 3.
2
Tecovirimat for smallpox infections.
Drugs Today (Barc). 2010 Feb;46(2):109-17. doi: 10.1358/dot.2010.46.2.1437244.
3
Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects.
Antimicrob Agents Chemother. 2010 Jun;54(6):2560-6. doi: 10.1128/AAC.01689-09. Epub 2010 Apr 12.
4
Global immunization: status, progress, challenges and future.
BMC Int Health Hum Rights. 2009 Oct 14;9 Suppl 1(Suppl 1):S2. doi: 10.1186/1472-698X-9-S1-S2.
5
Progressive vaccinia in a military smallpox vaccinee - United States, 2009.
MMWR Morb Mortal Wkly Rep. 2009 May 22;58(19):532-6.
7
Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246.
Antimicrob Agents Chemother. 2009 Jun;53(6):2620-5. doi: 10.1128/AAC.00021-09. Epub 2009 Apr 6.
8
ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification.
Antimicrob Agents Chemother. 2009 May;53(5):1817-22. doi: 10.1128/AAC.01596-08. Epub 2009 Feb 17.
9
Progress in the discovery of compounds inhibiting orthopoxviruses in animal models.
Antivir Chem Chemother. 2008;19(3):115-24. doi: 10.1177/095632020801900302.
10
Serine peptide phosphoester prodrugs of cyclic cidofovir: synthesis, transport, and antiviral activity.
Mol Pharm. 2008 Jul-Aug;5(4):598-609. doi: 10.1021/mp8000099. Epub 2008 May 16.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验